Denise Myshko

Senior Editor, OncLive®
Denise Myshko is your editorial contact for the Oncology Business Management section of OncologyLive, as well as the corporate newsletters. She joined OncologyLive in March 2020. Before that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@onclive.com

Articles

New HER2-Targeting Therapies Jostle for a Place in the Treatment Lineup

March 6th 2021

The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.

A More Simplified Health Care System is Needed to Provide Value

March 1st 2021

Although scientific advances in hematology and oncology have been extraordinary, the US health care system faces significant challenges in ensuring that patients receive high-quality, cost-effective care.

Investigators Aim Novel T-Cell Therapy at Solid Tumor Target

February 23rd 2021

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Coleman Looks Forward to a Big Year for New Cervical Cancer Therapies

February 15th 2021

Robert L. Coleman, MD, discusses key data for these therapies and touched on emerging developments concerning new therapies in ovarian and endometrial cancers.

Adjuvant Nivolumab Improves DFS in Patients With MIUC

February 13th 2021

February 13, 2021 - Nivolumab following surgery extended disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma.

Harnessing the Potential of Cell and Gene Therapy

February 4th 2021

Although safety remains a concern with gene therapy, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cured cancers will follow.

Seribantumab May Hold Pan-Tumor Potential in Cancers With NRG1 Fusions

February 3rd 2021

Investigators are seeking to determine whether seribantumab, a novel monoclonal antibody, can effectively treat patients with solid tumors that harbor rare NRG1 fusions.

Trial Explores Preoperative Window for Amcenestrant Therapy in Early Breast Cancer

February 2nd 2021

Investigators are seeking to determine whether amcenestrant can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer.

Updated Data Show Durable Response for Tepotinib in MET exon 14 Skipping NSCLC

January 31st 2021

Tepotinib demonstrated durable clinical activity in patients with MET exon 14 skipping non‒small cell lung cancer.

Big Data Tool Finds Variations in Treatment and Costs Across 3 Cancer Types

January 25th 2021

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

Oncology Influencers Explain Do’s and Don’t’s of Social Media

January 12th 2021

Oncologists discuss the use of social media in oncology.

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

January 6th 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.

Oncolytics Biotech Launches Trial of Pelareorep/Atezolizumab Combo in Difficult-to-Treat GI Cancers

December 30th 2020

December 30, 2020 - The phase 1/2 GOBLET trial will investigate the use of pelareorep in combination with atezolizumab in patients with metastatic colorectal and advanced or metastatic pancreatic and anal cancers.

BluePrint Subtyping Could be a Predictor of Pertuzumab Benefit in Early Breast Cancer

December 10th 2020

December 10, 2020 - Patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay, showed a trend for greater benefit with adjuvant pertuzumab therapy, according to an exploratory analysis of the data from the APHINITY trial.

Venetoclax/Rituximab Combo Demonstrates Sustained Benefit for Retreated Patients with CLL

December 8th 2020

December 8, 2020 - The combination of venetoclax and rituximab to retreat patients with relapsed/refractory chronic lymphocytic leukemia demonstrated a sustained time to next treatment benefit according to 5-year follow-up data of the MURANO study in a poster presentation at the 2020 ASH Meeting.

Oral Azacitidine Prolongs Survival in Patients with AML Following Induction, Consolidation Therapy

December 5th 2020

December 5, 2020 - Azacitidine, was shown to significantly prolong overall survival and relapse-free survival in patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy.

Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial

November 23rd 2020

November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC

November 11th 2020

Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.

Radiation Oncology Leaders Bristle Over New Medicare Payment Model

November 10th 2020

Practices and cancer centers in randomly selected zip codes will be required to participate in the new radiation oncology Model, which is expected to cover approximately 30% of eligible Medicare fee-for-service care episodes.

Hussain Discusses Progress of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer

November 5th 2020

PARP inhibitors have emerged as a promising therapeutic target in prostate cancer at the 38th Annual CFS® virtual conference.